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Abstract Residence of luminal ER proteins is mediated by a 
cyclic process which involves binding of escaped proteins to a 
KDEL receptor in a post-ER compartment and redistribution of 
the ligand-receptor complex back to the ER. We examined the 
relocation of the KDEL receptor after treatment with the fungal 
metabolite brefeldin A and compared this with the retrograde 
transport of the KDEL receptor observed after ligand or receptor 
overexpression. Incubation with brefeldin A led to the formation 
of vesicular structures containing the KDEL receptor and 
ERGIC-53, a marker for the ER-Golgi intermediate compart-
ment. Immunoelectron microscopy revealed that these structures 
are composed of tubulo-vesicular clusters. The brefeldin A 
induced vesicular structures were morphologically and biochemi-
cally distinct from the ER-Golgi hybrid compartment as 
demonstrated by double immunofluorescence microscopy and 
subcellular fractionation. Overexpression of the receptor itself or 
a lysozyme-KDEL construct led to a shift of the KDEL receptor 
together with ERGIC-53, an intermediate compartment marker 
to the ER but not to structures resembling BFA induced vesicular 
structures. Moreover, overexpression of the receptor resulted in 
the partial redistribution of marker proteins of the medial Golgi 
and the trans-Golgi network to ER-like structures. We conclude 
that the effects of brefeldin A on the redistribution of the KDEL 
receptor do not reflect physiological events occurring during 
increased occupancy of the receptor with ligands. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The Golgi complex is proposed to consist of at least three 
different compartments: the cis-most side of the Golgi/cis-
Golgi network (CGN) associated with an array of tubules, 
the medial Golgi and the trans Golgi/trans-Golgi network 
(TGN) (for review see [1]). The membranes and proteins 
transported out of the ER reach the CGN via the intermedi-
ate compartment (IC). The IC, also termed ER-Golgi inter-
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mediate compartment (ERGIC) [2], appears to consist of an 
extensive tubular network spread over large areas of the cy-
toplasm. The precise characterization of the CGN and IC is 
limited by the paucity of accepted marker proteins and the 
fact that these proteins are able to move between different 
compartments. Examples are ERGIC-53 [2] or its rat homo-
logue p58 [3] for the IC and the KDEL receptor [4,5] or gp74 
[6] for the CGN. 
Insight into the characteristics and dynamics of anterograde 
and retrograde transport has come from studies using the 
drug brefeldin A (BFA), which causes Golgi membranes to 
extend long uncoated tubules that fuse with the ER [7] result-
ing in an ER-Golgi hybrid compartment. Whether all parts of 
the Golgi complex fuse under BFA treatment with the ER is a 
matter of debate [8]. BFA reversibly blocks the first step in the 
formation of non-clathrin coat protein (COPI) coated trans-
port vesicles [9,10]. However, formation of COPII coated 
buds and vesicles which are involved in anterograde ER-Golgi 
transport in yeast are not inhibited by BFA [11]. A BFA-like 
fusion of Golgi cisternae with the ER was observed by over-
expression of bovine KDEL receptor [5] or a c-myc epitope 
tagged isoform of the KDEL receptor (ELP-1) [12]. These 
results raised the possibility that the effect of BFA and the 
phenotype of receptor overexpression are mechanistically re-
lated. In the course of our studies concerning the dynamics of 
the KDEL receptor and the nature of the retrograde traffic we 
directly compared all three mechanisms known to induce the 
redistribution of the KDEL receptor from the Golgi to the 
ER: treatment with BFA, the ligand induced redistribution of 
the KDEL receptor, and the overexpression of the receptor 
itself. 
2. Materials and methods 
2.1. Materials 
Brefeldin A was obtained from Epicenter Technologies (Madison, 
WI, USA) and uridine-5'-bisphospho-D-[3H]galactose from Amer-
sham-Buchler (Braunschweig, Germany). For transient expression of 
lysozyme-KDEL or the KDEL receptor (hERD2) the pCMV2 vector 
of Anderson et al. [13] was used, which was kindly provided by Dr. G. 
Thiel (Institute for Genetics, University of Cologne, Germany). The 
expression vector pBEH was a gift from Dr. C. Peters (Department of 
Biochemistry II, Gottingen, Germany). 
2.2. Antibodies 
Antibodies against different proteins or epitopes were produced 
according to standard procedures in the following species: NH2-
CLYITKVLKGKKLSLPA-COOH (ERD2^1) in rabbit; NH2-
CDFFYLYITKVLKGKKLSLPA-COOH (ERD2-6) in sheep; chick-
en lysozyme in guinea pig. Antibodies directed against the following 
antigens were generous gifts: ERGIC-53 (Gl/93) from H.P. Hauri 
(Department of Pharmacology, Basel, Switzerland) [14]; 8-COP 
from C. Harter (Department of Biochemistry, Heidelberg, Germany); 
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rabbit antibodies against a-mannosidase II from K. Moremen (Uni-
versity of Georgia, Athens, GA, USA) and M.G. Farquhar (Univer-
sity of California, La Jolla, CA, USA) [15]; monoclonal antibodies 
against a-mannosidase II from G. Warren (Imperial Cancer Research 
Fund, London, UK) (hybridoma clone 53FC3) [16] and TGN38 
(2F7.1) from G. Banting (University of Bristol, Bristol, UK) [17]. 
Monoclonal anti c-myc epitope antibodies (clone 9E10) as well as 
secondary antibodies coupled to fluorescein isothiocyanate (FITC), 
tetramethylrhodamine isothiocyanate (TRITC) or indigocarbocyanine 
(Cy3) were purchased from Dianova (Hamburg, Germany). 
2.3. cDNA cloning 
HepG2 RNA was purified according to [18] and used in a reverse 
PCR reaction with rTth polymerase (Perkin Elmer Cetus, Weiterstadt, 
Germany) with two 27-mer primers corresponding to the C- and N-
terminal sequences of the human KDEL receptor (hERD2) [19]. The 
product was cloned via the TA vector (Invitrogen, Leek, The Nether-
lands) into the mammalian expression vector pCMV2 [13]. The cDNA 
of ERD2myc was constructed [20] and cloned into the pBEH vector 
which allowed a moderate expression of the protein in COS cells. 
2.4. Subcellular fractionation 
Vero cells were grown to confluence on four 145 cm2 Petri dishes 
(Greiner, Nurtingen, Germany), treated with or without brefeldin A 
(2 ug/ml) for 60 min and washed with ice-cold PBS. The cells were 
collected, washed twice in homogenization buffer (130 mM NaCl, 50 
mM Tris-HCl pH 7.5, 30 mM KC1, 3 mM EDTA) and homogenized 
in the same buffer (0.5 ml/100 mg wet weight) by passing through 
syringe needles (5X22 G/0.7 mm, 5X24 G/0.55 mm). The homoge-
nate was centrifuged twice for 10 min at lOOOXg and the resulting 
post-nuclear supernatant (2 ml) layered on top of a step density gra-
dient (2 ml 30%, 1.33 ml 20%, 1.33 ml 15%, 1.33 ml 10%, 1.33 ml 
7.5%, 1.33 ml 5%, 1.33 ml 2.5% (w/v) Nycodenz) (Nycomed, Oslo, 
Norway). After centrifugation in a SW40 Rotor (Beckmann, Munich, 
Germany) for 15 min at 33000Xgav, nine fractions were collected 
from top to bottom. The marker enzymes rotenone-insensitive 
NADH cytochrome c reductase for the ER and UDP-galactosyltrans-
ferase (GalTf) for the Golgi were measured according to [21] and [22] 
respectively. Western and dot blot analyses were performed as given 
in [23] using a chemiluminescence kit (Boehringer Mannheim, Mann-
heim, Germany) for the detection of the peroxidase coupled secondary 
antibodies. The monoclonal antibody against ERGIC-53 does not 
recognize the protein in Western blots. 
2.5. Immunoelectron microscopy 
Vero cells were removed from the Petri dish (25 cm2) by treatment 
with 1 ml 20 |ig/ml proteinase K. After addition of 1 ml fixing sol-
ution (4% paraformaldehyde, 250 mM HEPES pH 7.4), cells were 
pelleted for 2 min at 1000Xg. The supernatant was removed and 
2 ml fresh fixing solution added. Subsequent processing was as de-
scribed elsewhere [24]. 
2.6. Immunofluorescence 
Cells grown on cover slips to about 50% confluence were trans-
ferred to 24 well plates (Greiner, Nurtingen, Germany). Treatment 
with brefeldin A was at 5 |ig/ml for different periods of time. Meth-
anol (—20°C, 2 min) was used for rapid fixation and permeabilization. 
Unspecific binding sites were blocked for 15 min with 0.2% (w/v) fish 
gelatine in PBS. Primary antibody incubations were performed for 1 h 
at room temperature in 4 mg bovine serum albumin/ml PBS and 
secondary antibodies in 0.2% (w/v) fish gelatine in PBS. Cover slips 
were mounted in Mowiol and viewed using a Zeiss Axioskop micro-
scope equipped with a Pan-Neofluar 100X/1.30 objective. 
2.7. Cell culture and transfection 
Vero cells (African green monkey kidney cells, ATCC CCL-81) and 
COS cells (SV40 transformed African green monkey kidney cells, 
ATCC CRL-1650) were grown as described in [23]. Transfections 
were carried out with the calcium phosphate coprecipitation method 
according to [25]. Unless otherwise stated cells were processed for 
immunofluorescence 24 h after transfection. 
Fig. 1. Double immunofluorescence of ERD2 (2-4) and ERGIC-53 (Gl/93) in Vero cells before (control) and after BFA treatment for 30 min. 
The images were obtained with a laser scan microscope. In untreated cells ERGIC-53 (intermediate compartment) overlaps partially with 
ERD2 (arrows). Application of 5 |lg/ml BFA for 30 min leads to a striking colocalization in BFA induced vesicular structures (BIVS). Bar, 
10 urn. 
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3. Results and discussion 
3.1. Different subcellular distribution of Man II and GalTf 
as compared to ERD2 and ERGIC-53 following BFA 
treatment 
In untreated cells ERD2 showed the known predominant 
localization in the perinuclear region, which was partially 
overlapping with ERGIC-53 (Fig. 1). In addition, a significant 
colocahzation between the peripheral punctuated elements of 
ERD2 and ERGIC-53 could be observed (Fig. 1, arrows). 
Treatment with BFA resulted in a nearly perfect colocahza-
tion of both proteins in dotted structures throughout the cy-
toplasm (Fig. 1) which are composed of clusters of tubulo-
vesicular structures with a lumen of 50-80 nm as shown by 
immunoelectron microscopy (Fig. 2). These BFA induced 
vesicular structures (BIVS) were different from the 'BFA 
bodies' described by [26] as they did not stain with 5-COP 
antibodies (data not shown). These BFA bodies have been 
described as a subcompartment of the ER and the site of 
accumulation of coatomer including 8-COP when the assem-
bly of COP coated vesicles is prevented by BFA. However, 
BIVS are probably identical to the 'Golgi related' remnants 
after BFA that contained preferentially ERGIC-53 [27] and to 
the 'smooth ER clusters' described by Saraste and Svensson 
[3] by immunoelectron microscopy. However, it is not clear 
whether BIVS comprise distinct structures or are somehow 
linked to the ER-Golgi hybrid compartment as suggested by 
results obtained in the presence of nocodazol and BFA [7]. 
Subcellular fractionation of Vero cells using Nycodenz gra-
dients revealed that ERD2 and ERGIC-53 are mostly present 
in the light fractions containing the trans Golgi marker GalTf. 
Treatment with BFA resulted in a significant shift of GalTf to 
ER fractions (Fig. 3, left panel). Surprisingly, the distribution 
of ERD2 and ERGIC-53 in the gradient was only marginally 
affected. 
It is well known that resident Golgi proteins like Man II 
redistribute to ER-like structures in the presence of BFA [7]. 
As the BFA induced redistribution of the KDEL receptor [5] 
and Man II [7] have been characterized only separately we 
reinvestigated the time course of BFA action and compared 
directly endogenous ERD2 and Man II using double immu-
nofluorescence. For reasons of antibody specificity we used 
NRK cells. In control cells, the KDEL receptor shows a Golgi 
pattern very similar to Man II and some additional peripheral 
punctuated structures. The ERD2 containing BIVS observed 
after 30 min of BFA treatment (Fig. 4) are indeed different 
from the ER-Golgi hybrid compartment stained with Man II 
antibodies. Importantly, a colocahzation of Man II with 
ERD2 could not be observed at any point of time during 
the BFA incubation. Even when the redistribution process 
was slowed down by incubating the cells at a reduced temper-
ature (20°C) there was neither a temporal nor a morpholog-
ical correlation between the distributions of ERD2 and Man 
II (results not shown). We cannot rule out the possibility that 
the portion of ERD2 that is present in Golgi structures be-
yond the CGN [28] becomes redistributed to the ER together 
with resident Golgi proteins but cannot be detected by immu-
nofluorescence. 
The effect of BFA on the redistribution of Golgi mem-
branes is reversible [29]. In contrast to the situation observed 
during BFA treatment the reconstruction of the Golgi appa-
ratus revealed a striking colocahzation between the KDEL 
Fig. 2. Immunoelectron microscopy of Vero cells before and after 
BFA treatment for 30 min using antibodies against ERD2. In con-
trol cells the KDEL receptor is mainly localized to Golgi cisternae 
as described previously [28]. In BFA treated cells there is a cluster 
of tubulo-vesicular structures marked for ERD2. Bar, 100 nm. 
receptor and Man II during the first 5-10 min after removal 
of BFA (Fig. 4). The first intermediate transport structures (5 
min) still resembled the BFA induced structures. This indi-
cates that Golgi enzymes move in a first stage from the ER-
Golgi hybrid compartment to the structures defined by pro-
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Fig. 3. Separation of BFA induced vesicular structures from the ER-Golgi hybrid compartment as revealed by subcellular fractionation of Vero 
cells. A postnuclear supernatant was subjected to a velocity controlled centrifugation on a Nycodenz gradient. Left panel: Rotenone-insensitive 
cytochrome c reductase (open boxes) denotes the position of ER membranes at the bottom of the gradient and GalTf (hatched boxes) the loca-
tion of Golgi membranes in the top fractions. A significant part of GalTf activity cofractionates with the ER fractions after treatment with 
BFA demonstrating the fusion of Golgi membranes with the endoplasmic reticulum. Right panel: Distribution of ERD2 (Western blots) and 
the intermediate compartment marker ERGIC-53 (dot blots) was not markedly affected upon BFA treatment. 
teins like ERD2 or ERGIC-53. The reconstruction of the 
Golgi was complete at about 30 min after removal of BFA 
as judged by the distribution of ERD2 and Man II. This 
suggests that under the conditions of BFA treatment there 
might be two different pathways for going back [30], but 
only one exit route after removal of the drug. There was no 
indication from our experiments that under these conditions 
the IC is somehow involved in the retrograde movement of 
resident Golgi proteins. 
We conclude from our results that two compartments are 
generated in the presence of BFA, one by fusion of the Golgi 
with ER membranes to form an ER-Golgi hybrid and the 
other by fusion of IC with the CGN membranes to build an 
IC-CGN hybrid (BIVS). As a consequence of this interpreta-
tion all proteins of the CGN or the IC should be localized in 
BIVS after BFA treatment. This assumption is in line with 
reports on similar morphological changes after BFA treat-
ment for proteins localized to the CGN: a peripherally asso-
ciated Golgi protein termed p210 and a transmembrane gly-
coprotein named gp74 colocalize in the presence of BFA with 
p58 [6,31], the rat homologue to ERGIC-53 [32]. This argu-
mentation predicts that all proteins which are concentrated in 
BIVS are localized either in the IC or in the CGN or in both 
compartments in the absence of BFA. 
Interestingly, a C-terminal myc tag impaired the BFA in-
duced localization of ERD2 to BIVS (not shown). The addi-
tion of BFA to COS cells which expressed ERD2myc at a 
moderate level resulted in a c-myc immunoreactivity in retic-
ular ER structures but not in BIVS. Surprisingly, in the same 
cells the peptide specific KDEL receptor antibodies revealed 
additional dotted structures that resembled the ERD2 pattern 
of BIVS in non-transfected cells (Fig. 1). We assume that the 
c-myc tag interferes with an epitope necessary for correct lo-
calization in the CGN [28]. A shift in the distribution of the 
tagged receptor to later Golgi compartments might have the 
consequence that it becomes redistributed together with resi-
dent Golgi proteins to the ER after incubation with BFA. 
However, the function of the c-myc tagged yeast receptor to 
retain a HDEL tagged invertase fusion protein was not im-
paired [33]. The influence of the C-terminal c-myc epitope 
revealed in our study may therefore well be without conse-
quence for the results obtained earlier using a c-myc tagged 
receptor [4,12]. 
3.2. Overexpression of ERD2 or lysozyme-KDEL is 
accompanied by redistribution of ERD2 and ERGIC-53 
to the ER but not to BFA induced vesicular structures 
Overexpression of an artificial KDEL receptor ligand was 
reported to cause the redistribution of the receptor from the 
Golgi to the ER [4,5]. We wanted to compare the ER struc-
tures of this approach with the BIVS. Transient expression of 
the secretory protein lysozyme tagged with a C-terminal 
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Fig. 4. Comparison of localization of endogenous ERD2 and Man II during treatment with brefeldin A. NRK cells were incubated with 5 u,g/ 
ml BFA for the indicated times (5, 30 min) and processed for double immunofluorescence. After 30 min ERD2 is concentrated in BFA induced 
vesicular structures (BIVS) that are clearly different from the ER pattern observed for Man II. After 30 min, BFA was washed out and cells 
examined after recovery for 5, 10 and 30 min. Despite their very different intracellular distribution before the BFA washout the KDEL receptor 
and Man II show a striking colocalization starting 5 min after BFA washout. After 30 min the distributions of both proteins were indistin-
guishable from control cells. Bar, 10 urn. 
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Fig. 5. Transient overexpression of hERD2 in COS and NRK cells causes location of ERGIC-53, Man II and TGN38 to the endoplasmic re-
ticulum. Overexpression in COS cells under the control of the strong cytomegalovirus promoter of pCMV2 led to a redistribution of hERD2 
together with ERGIC-53 to ER-like structures (a,b). The peptide specific antibody against ERD2 (ERD2^)-) was used in a concentration that 
enabled the recognition of hERD2 overexpressing cells. Note that only the transfected cell shows a diffuse staining pattern for hERD2 and 
ERGIC-53 in the ER. Overexpression of hERD2 causes a partial redistribution of Man II (c,d), 8-COP (e,f) and TGN38 (g,h) in NRK cells. 
Double immunofluorescence was performed using ERD2-4 in combination with monoclonal antibodies against TGN38 (2F7.1) and Man 
II (53FC3) and ERD2-6 together with 8-COP antibodies. Bar, 10 urn 
KDEL sequence [20] led to the disappearance of the promi-
nent Golgi staining of the KDEL receptor and the typical 
ERGIC-53 staining in transfected COS cells (not shown). A 
faint reticular staining colocalizing with lysozyme-KDEL in-
dicates that the KDEL receptor and ERGIC-53 had been 
redistributed to the ER. However, no BlV-like structures 
could be observed. 
An alternative way to induce retrograde transport is to 
overexpress the KDEL receptor itself. High level overexpres-
sion of the isoforms of the human ERD2, bovine p23 and 
human ELP-1 resulted in an ER-like co-staining of the Golgi 
marker Lens culinaris lectin in COS cells [5,12]. These results 
led to the suggestion that overexpression of ERD2 induces a 
phenotype identical to that observed during treatment with 
brefeldin A, and that both events might be mechanistically 
related [12]. As we observed that in contrast to the tagged 
ERD2myc the untagged KDEL receptor does not concentrate 
in the ER under BFA but colocalizes with ERGIC-53 in dis-
tinct vesicular structures (BIVS, Fig. 1), we reinvestigated this 
issue. We overexpressed an untagged version of human ERD2 
under the control of the strong cytomegalovirus promoter and 
compared the localization of ERD2 with the following marker 
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proteins: ERGIC-53 for the IC, M a n II for the medial Golgi, 
T G N 3 8 for the trans Golgi network and 5-COP for coated 
structures. For reasons of species specificity of the antibodies 
we used COS (ERGIC-53) and N R K (5-COP, M a n II, T G N 
38) cells. Most of the COS cells overexpressing h E R D 2 
showed a general redistribution of the receptor to the ER 
(Fig. 5a,b). Double immunofluorescence with antibodies 
against ERGIC-53 demonstrated that in these cells the IC 
marker had shifted to a very similar diffuse ER pattern but 
not to dotted vesicular structures as was observed during BFA 
treatment [7] (see also Fig. 1). Transient overexpression of 
h E R D 2 in N R K cells led to a weaker phenotype regarding 
E R D 2 since there always remained a Golgi-like staining in 
addition to the reticular ER pattern. The redistribution of 
h E R D 2 to the ER correlated with the redistribution of M a n 
II (Fig. 5c,d). T G N 3 8 was also redistributed to ER-like struc-
tures indicating that even the trans Golgi network was af-
fected by the overexpression of h E R D 2 (Fig. 5g,h). The peri-
nuclear staining of 8-COP shifted to a diffuse pattern 
representing either the ER or a cytosolic localization (Fig. 
5e,f). Together these results suggest that the entire Golgi com-
plex had been partially redistributed to the E R due to the 
increased amount of K D E L receptor. However there were 
no BIVS as observed for E R D 2 and ERGIC-53 after BFA 
treatment. 
In summary, we think it unlikely that the response to BFA 
and the overexpression of the receptor follow the same mech-
anism : First, in the presence of B F A proteins cycling between 
E R and Golgi like E R D 2 , ERGIC-53/p58 or gp74 are trans-
ferred not to the ER but to distinct structures (BIVS) and 
resident Golgi proteins do appear in the ER. Second, the 
ligand or receptor induced retrograde transport of E R D 2 
leads to the ER, and not to membrane structures resembling 
BIVS or IC. Third, recent evidence suggests that coatomer is 
an essential component for retrograde transport from the 
Golgi back to the ER [34], whereas BFA prevents the binding 
of coatomer to membranes. 
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